Linden Capital Partners and Audax Private Equity Invest in StatLab Medical Products
January 13, 2021
Audax Private Equity and Linden Capital Partners, two leading middle-market private equity firms, announced the acquisition of StatLab Medical Products. Founded in 1976 and headquartered in McKinney, Texas, StatLab is a leading manufacturer and distributor of consumables, reagents, and equipment used by anatomic pathology, molecular diagnostics, and other laboratories.
Cain Brothers was engaged to serve as Linden and Audax’s exclusive financial advisor based on its deep domain expertise and strong relationships in the Life Sciences and Diagnostics sector, as well as its long-standing relationship with both Audax and Linden.
StatLab Medical Products is leading the way in development and manufacturing of high-quality histology, cytology and immunohistochemistry diagnostic products. The Company partners with anatomic pathology, molecular diagnostics, and other laboratories to provide over 5,000 diagnostic products and equipment, delivered with expert support.
Audax Group is a leading alternative investment manager with offices in Boston, New York, and San Francisco. Since its founding in 1999, the firm has raised over $27 billion in capital across its Private Equity and Private Debt businesses. Audax Private Equity has invested over $6 billion in more than 135 platforms and over 900 add-on companies, and is currently investing out of its $3.5 billion, sixth private equity fund. With more than 250 employees and over 100 investment professionals, the firm is a leading capital partner for North American middle market companies.
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity firms. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Since its founding, Linden has invested more than $2 billion in healthcare companies and has raised nearly $3 billion of commitments.